论文部分内容阅读
目的 :观察血脂康胶囊对高胆固醇血症患者的调脂效果。 方法 :79例高胆固醇血症患者随机分成两组 :血脂康组(37例 ,0 .6 g,bid)与普伐他汀组 (42例 ,10 m g,qd)。服药前与服药 8周后测定血清总胆固醇 (TC)、甘油三酯 (TG)、低密度脂蛋白胆固醇 (L DL - C)、高密度脂蛋白胆固醇 (HDL - C)水平。结果 :服药 8周后 ,血脂康组与普伐他汀组患者的 TC比用药前降低 ,降幅分别为 2 1.7% (P<0 .0 5 )与 2 1.9% (P<0 .0 1) ;患者 L DL - C也比用药前降低 ,降幅依次为 34.9% (P<0 .0 1)与 33.2 %(P<0 .0 1) ;血脂康组患者 TG比用药前下降 2 0 .1% (P<0 .0 1) ,而普伐他汀组患者血清 TG仅降低 8.5 % (P>0 .0 5 )。 结论 :血脂康胶囊能够显著降低高胆固醇血症患者的血清 TC、L DL - C与 TG水平 ,可有效地用于高胆固醇血症患者的调脂治疗
Objective: To observe the lipid-lowering effect of Xuezhikang capsule on patients with hypercholesterolemia. Methods: 79 patients with hypercholesterolemia were randomly divided into two groups: Xuezhikang group (37 cases, 0.6 g, bid) and pravastatin group (42 cases, 10 m g, qd). Serum levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL - C) and high density lipoprotein cholesterol (HDL - C) were measured before medication and 8 weeks after medication. Results: After 8 weeks of treatment, TC in Xuezhikang group and pravastatin group was lower than that before treatment by 27.7% (P <0.05) and 2 1.9% (P <0.01), respectively. L DL-C was also lower than before treatment, decreasing by 34.9% (P <0.01) and 33.2% (P <0.01) respectively. The TG of Xuezhikang group decreased by 20.1% (P <0.01), while the serum TG in pravastatin group decreased by only 8.5% (P> 0.05). Conclusion: Xuezhikang Capsule can significantly reduce the levels of serum TC, L-DL-C and TG in patients with hypercholesterolemia and can be effectively used in lipid-lowering treatment of hypercholesterolemia patients